1. Home
  2. TMDX vs HAE Comparison

TMDX vs HAE Comparison

Compare TMDX & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TMDX
  • HAE
  • Stock Information
  • Founded
  • TMDX 1998
  • HAE 1971
  • Country
  • TMDX United States
  • HAE United States
  • Employees
  • TMDX N/A
  • HAE N/A
  • Industry
  • TMDX Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • HAE Medical/Dental Instruments
  • Sector
  • TMDX Health Care
  • HAE Health Care
  • Exchange
  • TMDX Nasdaq
  • HAE Nasdaq
  • Market Cap
  • TMDX 4.7B
  • HAE 3.8B
  • IPO Year
  • TMDX 2019
  • HAE 1991
  • Fundamental
  • Price
  • TMDX $88.36
  • HAE $91.05
  • Analyst Decision
  • TMDX Buy
  • HAE Strong Buy
  • Analyst Count
  • TMDX 10
  • HAE 8
  • Target Price
  • TMDX $138.20
  • HAE $107.88
  • AVG Volume (30 Days)
  • TMDX 2.2M
  • HAE 695.6K
  • Earning Date
  • TMDX 10-28-2024
  • HAE 11-07-2024
  • Dividend Yield
  • TMDX N/A
  • HAE N/A
  • EPS Growth
  • TMDX N/A
  • HAE N/A
  • EPS
  • TMDX 0.94
  • HAE 2.41
  • Revenue
  • TMDX $401,090,000.00
  • HAE $1,361,223,000.00
  • Revenue This Year
  • TMDX $83.25
  • HAE $7.71
  • Revenue Next Year
  • TMDX $26.27
  • HAE $4.89
  • P/E Ratio
  • TMDX $94.29
  • HAE $37.83
  • Revenue Growth
  • TMDX 109.09
  • HAE 9.84
  • 52 Week Low
  • TMDX $63.86
  • HAE $70.25
  • 52 Week High
  • TMDX $177.37
  • HAE $97.97
  • Technical
  • Relative Strength Index (RSI)
  • TMDX 31.88
  • HAE 75.64
  • Support Level
  • TMDX $82.70
  • HAE $70.25
  • Resistance Level
  • TMDX $98.88
  • HAE $94.99
  • Average True Range (ATR)
  • TMDX 5.52
  • HAE 2.49
  • MACD
  • TMDX 1.30
  • HAE 2.09
  • Stochastic Oscillator
  • TMDX 15.58
  • HAE 86.84

About TMDX TransMedics Group Inc.

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

About HAE Haemonetics Corporation

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Share on Social Networks: